Do AI chatbots give reliable answers on cancer? Yes and noSeptember 1, 2023Breast CancerLung CancerGenitourinary CancerMelanomaProstate Cancer
New trials in prostate cancer: Could your patient benefit?August 25, 2023Genitourinary CancerProstate Cancer
Risky drinking common in cancer survivorsAugust 24, 2023OncologyMental HealthMixed TopicsProstate Cancer
Race and Age-Related PSA Testing Disparities in Spinal Cord Injured Men: Analysis of National Veterans Health Administration DataAugust 15, 2023Prostate Cancer
FDA OKs combo therapy of niraparib, abiraterone acetate for prostate cancerAugust 14, 2023Genitourinary CancerProstate Cancer
MRI-guided SBRT cuts radiation toxicity in prostate cancerJuly 26, 2023Genitourinary CancerProstate Cancer
‘Treatment holiday’ in prostate cancer with tailored dosingJuly 25, 2023Genitourinary CancerProstate Cancer
Cancer Data Trends 2023July 5, 2023CancerBreast CancerGenitourinary CancerLung CancerProstate CancerColon and RectalNeurology
Promising New Approaches for Testicular and Prostate CancerJuly 5, 2023Prostate CancerGenitourinary CancerCancer
Risk of falls seen with newer antiandrogens for prostate cancerJune 9, 2023Genitourinary CancerProstate Cancer
COVID can mimic prostate cancer symptomsMarch 21, 2023COVID-19 UpdatesGenitourinary CancerPulmonologyInfectious DiseasesLong COVIDPainProstate Cancer
Prostate cancer subgroup may benefit from intensified therapyMarch 1, 2023Genitourinary CancerProstate CancerOncology
Talazoparib add-on improves outcomes in metastatic prostate cancerFebruary 22, 2023Genitourinary CancerProstate Cancer
Rucaparib benefit in BRCA+ prostate cancer confirmedFebruary 17, 2023Genitourinary CancerProstate Cancer
